Advertisement

Topics

Advaxis Company Profile

23:58 EDT 25th September 2017 | BioPortfolio

Advaxis, Inc. is a biotechnology company that uses a modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. Based upon over a 10 years of innovative work done by Yvonne Paterson, Ph.D., Professor of Microbiology at the University of Pennsylvania, it has been found that the unique microbe Listeria monocytogenes is capable of stimulating numerous aspects of the immune system simultaneously; coordinating innate, humoral (antibody), and cellular adaptive immune responses in an extremely effective response to existing cancers and other diseases. Unlike other therapeutic approaches, in pre-clinical research Advaxis’ Listeria technology has been able to consistently demonstrate complete therapeutic responses resulting in complete tumor regression.

Location

The Technology Centre of New Jersey Suite 117
675 U.S. Route 1
North Brunswick
08902
United States of America

Contact

Phone: 732-545-1590
Fax: 732-545-1084
Email: BD@advaxis.com


News Articles [39 Associated News Articles listed on BioPortfolio]

O’Connor Resigns From Advaxis, Lombardo Named Interim CEO

Daniel O’Connor has resigned from his positions as CEO, president, and board member of Princeton, NJ-based Advaxis (NASDAQ: ADXS). No reason for O’Connor’s resignation was given in a company new...

Advaxis shares tumble after CEO quits

Daniel O’Connor has resigned as chief executive of US biotech Advaxis.

Advaxis gives progress report on I-O programs using listeria-based technology

American immuno-oncology specialist Advaxis has provided detailed development updates on its nine clinical…

O’Connor steps down as CEO of Advaxis

Daniel J. O’Connor, chief executive officer, president and board member of Advaxis, Inc., a late-stage biotechnology company focused on the discovery, development and commercialization of a propriet...

Bristol to study Opdivo combination with Advaxis in cervical cancer

Bristol-Myers Squibb Co. teamed up with Advaxis Inc. to study a combination of BMS's Opdivo (nivolumab) and Advaxis' ADXSDUAL in women with persistent, recurrent, or metastatic (squamous or non-squamo...

Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders

Thursday, July 13th 2017 at 1:06pm UTC Axalimogene Filolisbac Phase 2 Data and Investigational Mechanism of Action Featured by Oncology Researchers PRINCETON, N.J.–(BUSINESS WIRE)– Advaxis...

Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial

Potentially registrational trial of ADXS-DUAL Listeria-based vaccine with Bristol's PD-1 inhibitor Opdivo in recurrent metastatic cervical cancer will complement Advaxis's...   

Advaxis, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Updated: 06052017] Prices from USD $350

Advaxis, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Advaxis, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report include...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [5 Associated Companies listed on BioPortfolio]

Advaxis, Incorporated

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor...

Advaxis, Inc. and Rodman & Renshaw, LLC

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform tech...

Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate ...

Advaxis Incorporated

Advaxis is a biotechnology company developing proprietary, live but attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate ...

Advaxis

Advaxis, Inc. is a biotechnology company that uses a modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. Based upon over a 10 yea...

More Information about "Advaxis" on BioPortfolio

We have published hundreds of Advaxis news stories on BioPortfolio along with dozens of Advaxis Clinical Trials and PubMed Articles about Advaxis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Advaxis Companies in our database. You can also find out about relevant Advaxis Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record